The Opioid-Induced Constipation Treatment Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The market for opioid-induced constipation treatment has seen substantial growth lately. The market value is anticipated to increase from $1.78 billion in 2024 to $1.9 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 7.0%.
The opioid-induced constipation treatment market is projected to reach $2.47 billion by 2029, with a compound annual growth rate (CAGR) of 6.7%.
Download Your Free Sample of the 2025 Opioid-Induced Constipation Treatment Market Report and Uncover Key Trends Now!The drivers in the opioid-induced constipation treatment market are:
• Expanding geriatric population
• Personalized OIC treatments
• Availability of effective OIC drugs
• Rising prevalence of gastrointestinal disorders
The opioid-induced constipation treatment market covered in this report is segmented –
1) By Drug Class: Laxatives, Peripherally Acting µ-opioid Receptor Antagonists, Serotonin Receptor Agonists, Prostaglandin
2) By Type: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
The trends in the opioid-induced constipation treatment market are:
• Patient education and awareness is a prominent emerging trend in the market.
• The emergence of targeted therapies is shaping the future of the opioid-induced constipation treatment market.
• Non-pharmacological interventions are becoming increasingly popular.
• Biotechnology innovations and increased investment are key emerging trends influencing the market.
The major players in the opioid-induced constipation treatment market are:
• Pfizer Inc.
North America was the largest region in the opioid-induced constipation treatment market in 2024